NEWS & EVENTS

Noema Pharma receives FDA Fast Track designation

BASEL, Switzerland, October 18, 2022 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food …

Noema Pharma announces completion of enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) validation studY

Study to validate the novel Patient-Reported Electronic Diary designed to more efficiently and accurately measure disease burden associated with trigeminal neuralgia LIBRATN (NOE-101 Phase 2/3 …

Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder

Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering) Top-line data expected in Q4 …

Noema Pharma announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b study of PDE10A inhibitor gemlapodect (NOE-105) in Childhood Onset Fluency Disorder

Efficacy and safety study evaluating gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering) Top-line data expected in Q4 2023 BASEL, …

Noema Pharma to attend and present at BioEquity Europe and UBS Global Healthcare Conference in May 2022

BASEL, Switzerland, May 6, 2022 – Noema Pharma, a Swiss clinical-stage Biotech company targeting debilitating central nervous system (CNS) indications, today announces Luigi Costa, Chief Executive …

Noema Pharma appoints Michael Gutch as Chief Financial Officer

BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of …

Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia

Study evaluating the efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical …

Noema Pharma announces publication of “Noema, Basimglurant and a New Clinical Trial for Seizures in TSC” podcast on TSC Alliance website

BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces that the TSC …

Noema Pharma announces FDA Investigational New Drug authorization for Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia

Study to evaluate efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, February 14, 2022 – Noema Pharma, a Swiss-based clinical …

Trigeminal Neuralgia – You are not alone, Hosted by Noema Pharma

BASEL, Switzerland, February 8, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announced that it will …

Noema Pharma Hosting Key Opinion Leader Webinar on Stuttering

BASEL, Switzerland, December 8, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announced that it will …

Noema Pharma expands its Board of Directors with the appointments of Catherine Moukheibir and Ilise Lombardo

BASEL, Switzerland, November 9, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of …

Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

BASEL, Switzerland, October 4, 2021 –Noema Pharma AG, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of …

Noema Pharma to attend Swiss Biotech Day and the UBS Biotech Private Company Symposium in September 2021

BASEL, Switzerland, September 2, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces it will attend …

Noema Pharma initiates Phase 2a Allevia study of PDE10A inhibitor NOE-105 in Tourette Syndrome

First Noema clinical trial, with asset in-licensed from Roche with strong clinical safety package Noema advancing potentially life-changing therapeutics for patients without satisfactory treatments Basel, …

Noema Pharma to Host a Key Opinion Leader Webinar on Seizures in Tuberous Sclerosis Complex

BASEL, Switzerland, July 7, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, will host a key opinion …

Noema Pharma to Attend Investor Conferences in June and July 2021

BASEL, Switzerland, May 31, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, today announces it will attend …